Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGT003 in Advanced Solid Tumors
NCT07811037Phase 2Recruiting
- Sponsor
- Sungen Biomedical
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SGT-003 in solid tumor, sponsored by Sungen Biomedical. Primary endpoints: Adverse Events and immune-related Adverse Events, Dose Limit Toxicity and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
SGT-003
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07811037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811037.